ArticleCancer biology & medicine2020
Characterization of 500 Chinese patients with cervical esophageal cancer by clinicopathological and treatment outcomes.
Abstract read
In one paragraph
Article in Cancer biology & medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Definitive chemo-radiotherapy in cervical oesophageal cancer: a comprehensive review of literature.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024Review
- Elective nodal irradiation versus involved-field irradiation for stage II-IV cervical esophageal squamous cell carcinoma patients undergoing definitive concurrent chemoradiotherapy: a retrospective propensity study with 8-year survival outcomes.Radiation oncology (London, England) · 2023Article
- Increases prognostic value of clinical-pathological nomogram in patients with esophageal squamous cell carcinoma.Frontiers in oncology · 2023Article
- The High Expression of p53 Is Predictive of Poor Survival RatherJournal of oncology · 2023Article
- Update on Management of Squamous Cell Esophageal Cancer.Current oncology reports · 2022Review
- Long-term effect of hospital volume on the postoperative prognosis of 158,618 patients with esophageal squamous cell carcinoma in China.Frontiers in oncology · 2022Article
- Long-Term Survival Outcomes and Comparison of Different Treatment Modalities for Stage I-III Cervical Esophageal Carcinoma.Frontiers in medicine · 2021Article
- Apolipoprotein C1 (APOC1): A Novel Diagnostic and Prognostic Biomarker for Cervical Cancer.OncoTargets and therapy · 2020Article
- CircAMOTL1 Promotes Tumorigenesis Through miR-526b/SIK2 Axis in Cervical Cancer.Frontiers in cell and developmental biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Peinan ChenState Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Xueke ZhaoState Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Fuyou ZhouState Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Xin SongState Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Shoujia HuState Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Yan JinState Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Xianzeng WangDepartment of Thoracic Surgery, Linzhou People's Hospital, Linzhou 456550, China.
Xuena HanState Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Zongmin FanState Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Ran WangState Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Bei LiState Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Wenli HanState Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Panpan WangState Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Jilin LiDepartment of Pathology, Linzhou Esophageal Cancer Hospital, Linzhou 456550, China.
Lixin WanDepartment of Oncology, Nanyang Central Hospital, Nanyang 473000, China.
Liguo ZhangDepartment of Thoracic Surgery, Xinxiang Central Hospital, Xinxiang 453000, China.
Qide BaoDepartment of Oncology, Anyang District Hospital, Anyang 455000, China.
Fubao ChangDepartment of Thoracic Surgery, Linzhou Center Hospital, Linzhou 456550, China.
Yanru QinState Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Zhiwei ChangState Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.
Jianwei KuDepartment of Gastroenterology, The Second Affiliated Hospital of Nanyang Medical College, Nanyang 473000, China.
Haijun YangDepartment of Pathology, Anyang Tumor Hospital, Anyang 455000, China.
Ling YuanDepartment of Radiotherapy, The Affiliated Cancer Hospital of Zhengzhou University (Henan Cancer Hospital), Zhengzhou 450000, China.
Jingli RenDepartment of Pathology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Xuemin LiDepartment of Pathology, Hebei Provincial Cixian People's Hospital, Cixian 056500, China.
Lidong WangState Key Laboratory of Esophageal Cancer Prevention & Treatment and Henan Key Laboratory for Esophageal Cancer Research of The First Affiliated Hospital, Zhengzhou University, Zhengzhou 450052, China.ORCID 0000-0001-5103-8226
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
EsophagectomyAgedChemoradiotherapy, AdjuvantChemotherapy, AdjuvantChinaEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagusFemaleFollow-Up StudiesHumansLaryngectomyMaleMiddle AgedNeckNeoplasm StagingCervical esophageal canceresophagectomyradiochemotherapysurvival
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.